Pristane-induced autoimmunity in germ-free mice

Akiei Mizutani, Victoria M. Shaheen, Hideo Yoshida, Jun Akaogi, Yoshiki Kuroda, Dina C. Nacionales, Yoshioki Yamasaki, Michito Hirakata, Nobutaka Ono, Westley H. Reeves, Minoru Satoh

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Hypergammaglobulinemia and autoantibodies are reduced in pristane-treated specific pathogen-free mice vs. conventionally housed controls, consistent with the role of microbial stimulation in this model. To determine whether microbial stimulation is required, BALB/c mice housed under germ-free conditions were treated i.p. with sterile PBS or pristane and examined 6 months later. As in conventional mice, pristane-treated germ-free mice developed peritoneal granulomas and hypergammaglobulinemia with increased IgG2a/IgG1 ratios. LPS stimulation induced more IL-6, IL-12, and TNF-α, and anti-CD3 induced more IFN-γ and IL-4 by peritoneal cells from pristane-treated mice vs. control. Anti-nRNP/Sm and -Su autoantibodies were found in 40% and 43%, respectively, of pristane-treated germ-free mice by immunoprecipitation. Thus, bacterial stimulation was not required for lupus autoantibodies, peritoneal granuloma formation, hypergammaglobulinemia, or cytokine overproduction. Although microbial stimulation acts synergistically with pristane, these results clearly indicate that pristane does not act merely by increasing exposure to microbial products such as LPS.

Original languageEnglish
Pages (from-to)110-118
Number of pages9
JournalClinical Immunology
Volume114
Issue number2
DOIs
Publication statusPublished - 2005 Feb

Fingerprint

Autoimmunity
Hypergammaglobulinemia
Autoantibodies
Granuloma
Specific Pathogen-Free Organisms
Interleukin-12
pristane
Immunoprecipitation
Interleukin-4
Interleukin-6
Immunoglobulin G
Cytokines

Keywords

  • Autoantibodies
  • Cytokines
  • Inflammation
  • Lupus
  • Microbial environment
  • Pristane

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Mizutani, A., Shaheen, V. M., Yoshida, H., Akaogi, J., Kuroda, Y., Nacionales, D. C., ... Satoh, M. (2005). Pristane-induced autoimmunity in germ-free mice. Clinical Immunology, 114(2), 110-118. https://doi.org/10.1016/j.clim.2004.09.010

Pristane-induced autoimmunity in germ-free mice. / Mizutani, Akiei; Shaheen, Victoria M.; Yoshida, Hideo; Akaogi, Jun; Kuroda, Yoshiki; Nacionales, Dina C.; Yamasaki, Yoshioki; Hirakata, Michito; Ono, Nobutaka; Reeves, Westley H.; Satoh, Minoru.

In: Clinical Immunology, Vol. 114, No. 2, 02.2005, p. 110-118.

Research output: Contribution to journalArticle

Mizutani, A, Shaheen, VM, Yoshida, H, Akaogi, J, Kuroda, Y, Nacionales, DC, Yamasaki, Y, Hirakata, M, Ono, N, Reeves, WH & Satoh, M 2005, 'Pristane-induced autoimmunity in germ-free mice', Clinical Immunology, vol. 114, no. 2, pp. 110-118. https://doi.org/10.1016/j.clim.2004.09.010
Mizutani A, Shaheen VM, Yoshida H, Akaogi J, Kuroda Y, Nacionales DC et al. Pristane-induced autoimmunity in germ-free mice. Clinical Immunology. 2005 Feb;114(2):110-118. https://doi.org/10.1016/j.clim.2004.09.010
Mizutani, Akiei ; Shaheen, Victoria M. ; Yoshida, Hideo ; Akaogi, Jun ; Kuroda, Yoshiki ; Nacionales, Dina C. ; Yamasaki, Yoshioki ; Hirakata, Michito ; Ono, Nobutaka ; Reeves, Westley H. ; Satoh, Minoru. / Pristane-induced autoimmunity in germ-free mice. In: Clinical Immunology. 2005 ; Vol. 114, No. 2. pp. 110-118.
@article{1e299f9aef054b75bbbb816429109f9d,
title = "Pristane-induced autoimmunity in germ-free mice",
abstract = "Hypergammaglobulinemia and autoantibodies are reduced in pristane-treated specific pathogen-free mice vs. conventionally housed controls, consistent with the role of microbial stimulation in this model. To determine whether microbial stimulation is required, BALB/c mice housed under germ-free conditions were treated i.p. with sterile PBS or pristane and examined 6 months later. As in conventional mice, pristane-treated germ-free mice developed peritoneal granulomas and hypergammaglobulinemia with increased IgG2a/IgG1 ratios. LPS stimulation induced more IL-6, IL-12, and TNF-α, and anti-CD3 induced more IFN-γ and IL-4 by peritoneal cells from pristane-treated mice vs. control. Anti-nRNP/Sm and -Su autoantibodies were found in 40{\%} and 43{\%}, respectively, of pristane-treated germ-free mice by immunoprecipitation. Thus, bacterial stimulation was not required for lupus autoantibodies, peritoneal granuloma formation, hypergammaglobulinemia, or cytokine overproduction. Although microbial stimulation acts synergistically with pristane, these results clearly indicate that pristane does not act merely by increasing exposure to microbial products such as LPS.",
keywords = "Autoantibodies, Cytokines, Inflammation, Lupus, Microbial environment, Pristane",
author = "Akiei Mizutani and Shaheen, {Victoria M.} and Hideo Yoshida and Jun Akaogi and Yoshiki Kuroda and Nacionales, {Dina C.} and Yoshioki Yamasaki and Michito Hirakata and Nobutaka Ono and Reeves, {Westley H.} and Minoru Satoh",
year = "2005",
month = "2",
doi = "10.1016/j.clim.2004.09.010",
language = "English",
volume = "114",
pages = "110--118",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Pristane-induced autoimmunity in germ-free mice

AU - Mizutani, Akiei

AU - Shaheen, Victoria M.

AU - Yoshida, Hideo

AU - Akaogi, Jun

AU - Kuroda, Yoshiki

AU - Nacionales, Dina C.

AU - Yamasaki, Yoshioki

AU - Hirakata, Michito

AU - Ono, Nobutaka

AU - Reeves, Westley H.

AU - Satoh, Minoru

PY - 2005/2

Y1 - 2005/2

N2 - Hypergammaglobulinemia and autoantibodies are reduced in pristane-treated specific pathogen-free mice vs. conventionally housed controls, consistent with the role of microbial stimulation in this model. To determine whether microbial stimulation is required, BALB/c mice housed under germ-free conditions were treated i.p. with sterile PBS or pristane and examined 6 months later. As in conventional mice, pristane-treated germ-free mice developed peritoneal granulomas and hypergammaglobulinemia with increased IgG2a/IgG1 ratios. LPS stimulation induced more IL-6, IL-12, and TNF-α, and anti-CD3 induced more IFN-γ and IL-4 by peritoneal cells from pristane-treated mice vs. control. Anti-nRNP/Sm and -Su autoantibodies were found in 40% and 43%, respectively, of pristane-treated germ-free mice by immunoprecipitation. Thus, bacterial stimulation was not required for lupus autoantibodies, peritoneal granuloma formation, hypergammaglobulinemia, or cytokine overproduction. Although microbial stimulation acts synergistically with pristane, these results clearly indicate that pristane does not act merely by increasing exposure to microbial products such as LPS.

AB - Hypergammaglobulinemia and autoantibodies are reduced in pristane-treated specific pathogen-free mice vs. conventionally housed controls, consistent with the role of microbial stimulation in this model. To determine whether microbial stimulation is required, BALB/c mice housed under germ-free conditions were treated i.p. with sterile PBS or pristane and examined 6 months later. As in conventional mice, pristane-treated germ-free mice developed peritoneal granulomas and hypergammaglobulinemia with increased IgG2a/IgG1 ratios. LPS stimulation induced more IL-6, IL-12, and TNF-α, and anti-CD3 induced more IFN-γ and IL-4 by peritoneal cells from pristane-treated mice vs. control. Anti-nRNP/Sm and -Su autoantibodies were found in 40% and 43%, respectively, of pristane-treated germ-free mice by immunoprecipitation. Thus, bacterial stimulation was not required for lupus autoantibodies, peritoneal granuloma formation, hypergammaglobulinemia, or cytokine overproduction. Although microbial stimulation acts synergistically with pristane, these results clearly indicate that pristane does not act merely by increasing exposure to microbial products such as LPS.

KW - Autoantibodies

KW - Cytokines

KW - Inflammation

KW - Lupus

KW - Microbial environment

KW - Pristane

UR - http://www.scopus.com/inward/record.url?scp=19944429660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429660&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2004.09.010

DO - 10.1016/j.clim.2004.09.010

M3 - Article

C2 - 15639644

AN - SCOPUS:19944429660

VL - 114

SP - 110

EP - 118

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -